Search

First randomized evidence for kinase inhibitor activity in acute myeloid leukemia

Despite the success of tyrosine kinase inhibitors in some forms of leukemias such as chronic myeloid leukemia and acute lymphoblastic leukemia, until now a kinase inhibitor had yet to demonstrate activity in acute myeloid leukemia (AML).

Read more

Blood Disorders: European Hematologists gather in Stockholm, June 13-16, 2013

About the EHA Annual Congress

Hematology is a specialty that covers everything to do with blood: its origin in the bone marrow, diseases of blood and their treatments.

Read more

Highlights from the SWG

Events
The ERIC International Preceptorship, Realizing Precision Medicine in CLL: Why and How
Stresa, Italy
November 17–18, 2023
PublicationsRecent ERIC publications include:

The evolving landscape of COVID-19 and post-COVID condition in patients with chronic lymphocytic leukemia
Other malignancies in the history of CLL: an international multicenter study conducted…

Read more

Revising the ICH Guidelines on Clinical Trials

The EHA delegation to the ICH meeting: from left to right, Professors Christian Gisselbrecht, Steven Le Gouill and Martin Dreyling. Clinical trials and drug development have become more complex over the years.

Read more

Second EHA-SAH tutorial in Argentina, another success

Hematologists from South America and mainland US gathered in Argentina on September 14-15 for brain-stretching exercises on the topics of lymphoid malignancies and plasma cell dyscrasias.

Read more

EHA Award winners put in the spotlight in Copenhagen

The EHA-José Carreras Non-Clinical Junior Fellowship is made possible with the support of the German José Carreras Foundation.

Read more

EHA Lymphoma Group

The EHA Lymphoma Group (EHA LyG) is a specialized working group that was established in 2014.

Read more

SWG Education Activities

Session at EHA2023The EHA2023 Congress was held in Frankfurt in June 2023. During the event, we held a session with the EHA Adolescent and Young Adult (AYA) Taskforce on the treatment of AYA patients with acute lymphoblastic leukaemia (ALL).

Read more